newsfilter
← Latest News
Business Wire·

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • On August 20, 2026, Zura Bio Limited granted inducement awards of options to purchase up to 587,000 Class A Ordinary Shares to thirteen newly hired employees.
  • The awards were approved by the Compensation Committee & granted outside the 2023 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each option has an exercise price of $5.75 per share, matching the closing price on the grant date.
  • The options vest over four years, with 25% vesting on the one-year anniversary & the remainder vesting in equal quarterly installments thereafter.
  • Zura is a clinical-stage biotechnology company developing dual-pathway antibodies for autoimmune & inflammatory diseases.
  • Lead candidate tibulizumab (ZB-106) is in two Phase 2 studies: TibuSHIELD for hidradenitis suppurativa & TibuSURE for systemic sclerosis.
  • Additional candidates torudokimab (ZB-880) & crebankitug (ZB-168) have completed Phase 1/1b studies & are being evaluated for various conditions.